Drug Trial Radar · NCT06280235
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
243
Actual
Start
Mar 27, 2024
Primary completion
Feb 26, 2025
Study completion Mar 28, 2025
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants continue their standard therapy throughout the study. Participants are put into 4 groups by chance. 3 of the 4 groups take different doses of BI 1569912. 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks. Participants are in the study for about 2 to 4 and a half months. During this time, they visit the study site at least 6 times. At the visits, doctors ask participants about their symptoms. The participants answer questions about their depression symptoms. The results are compared between the groups. The doctors also regularly check the general health of participants.
Conditions
- Depressive Disorder, Major
Interventions
BI 1569912Drug
Tablets
PlaceboDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in MADRS Total Score at Week 6Time frame: MMRM included measurements from baseline and Day 8, Week 4, Week 6 after first drug administration. MMRM estimates of change from baseline to Week 6 in MADRS total score is reported.
Locations
52 sites in 7 countries. Site status is shown where the registry gives one.
Southwest Biomedical Research, LLC
Tucson, Arizona
Excell Research Inc.
Oceanside, California
NRC Research Institute
Orange, California
Asclepes Research Centers-Panorama City-62905
Panorama City, California
CT Clinical Research
Cromwell, Connecticut
Galiz Research
Hialeah, Florida
Premier Clinical Research Institute
Miami, Florida
CCM Clinical Research Group, LLC-Miami-68482
Miami, Florida
iResearch Atlanta
Decatur, Georgia
Chicago Research Center, Incorporated
Chicago, Illinois
ActivMed Practices & Research
Methuen, Massachusetts
Boston Clinical Trials
Roslindale, Massachusetts
Adams Clinical
Watertown, Massachusetts
Hassman Research Institute-Marlton-66897
Marlton, New Jersey
Neurobehavioral Research, Inc.
Cedarhurst, New York
Midwest Clinical Research
Dayton, Ohio
Neuro-Behavioral Clinical Research
North Canton, Ohio
Sooner Clinical Research
Oklahoma City, Oklahoma
Houston Clinical Trials, LLC
Bellaire, Texas
Grayline Research Center
Wichita Falls, Texas
Northwest Clinical Research Center
Bellevue, Washington
Anima Research Center
Alken, Belgium
Universitair Psychiatrisch Centrum Duffel (UPC Duffel)
Duffel, Belgium
Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry - Dr Ivo Natsov
Cherven Bryag, Bulgaria
MHC - Ruse, EOOD
Rousse, Bulgaria
Medical Center "Sv.Naum"
Sofia, Bulgaria
DCC "Sv. Vrach and Sv. Sv. Kuzma and Damyan" OOD
Sofia, Bulgaria
Medical Center Hera EOOD
Sofia, Bulgaria
Medical Center Intermedica Ltd.
Sofia, Bulgaria
DCC Mladost-M Varna OOD
Varna, Bulgaria
Hebei Mental Health Center
Baoding, China
Beijing Anding Hospital
Beijing, China
Peking University Sixth Hospital
Beijing, China
The Second Xiangya Hospital Of Central South University
Changsha, China
Shanghai Mental Health Center
Shanghai, China
Shenzhen Kangning Hospital
Shenzhen, China
The First Hospital of Hebei Medical University
Shijiazhuang, China
Tianjin Anding Hospital
Tianjin, China
A-SHINE s.r.o
Pilsen, Czechia
Clintrial s.r.o.
Prague, Czechia
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.